Biomarkers for Drug-Induced Kidney Injury Get Boost From EMA, FDA

Clinical Trials Advisor
A A
The European Medicines Agency is lending support to an initiative to qualify biomarkers that can provide early warning of an investigational compound’s risks of causing drug-induced kidney injuries.

To View This Article:

Login

Subscribe To Clinical Trials Advisor